Lecanemab.
Is it really working?
So, the data seems to indicate that administering this drug will retard cognitive and functional decline by 27%, when compared to a placebo. That’s good news for Eisai and Biogen- as well as perhaps for Eli Lilly which is concurrently testing its own anti-amyloid drug for Alzheimer’s.
Continue reading Is this worth taking?
Share this:
